Clinical Trials

If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815-730-3098.


ISO-CC-007: 1st-line Metastatic Colorectal
A randomized, multi-center, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer


Relapsed/Refractory Hodgkin Lymphoma – E4412
A Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma



EA6134 : First-Line Metastatic Melanoma
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma


EAA173: 1st-line high risk Smoldering Multiple Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma


EA8153 : 2nd line Metastatic Prostate
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial


Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study


A221504 : Advanced IIIB or IV advanced NSCL
A Randomized, Double-Blind, Placebo-Controlled Pilot Study Of An Oral, Selective Peripheral Opioid Receptor Antagonist In Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)
NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)
ANAM 17-20 : Weightloss in NSCLC
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
EA5163 : Advanced Nonsquamous NSCLC
A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
M14-239 : 2nd-Line NSCLC
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer


A031704 - 1st-line Metastatic Renal Cell
PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated Renal Cell Cancer


Exact Sciences 2018-01 : Biomarkers on Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors: Breast, Lung, Coorectal, Prostate, Bladder, Uterine, Kidney/Renal Pelvis, Pancreatic, Liver, Stomach, Ovarian or Esophageal
Observational: Risk of Febrile Neutopernia – 20170758 Amgen
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia among Subjects with Non-myeloid Malignancies at High Risk for Febrile Neutropenia and receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Collection and Distribution of Biofluids and Tumor Tissue Biospecimens for Research Purposes - IPROCESS-BSG-001-US Advarra IRB 1/14/2019 - Bluestar Genomics
Untreated - Bladder, Brain, Breast, Cervical, Colorectal, Esophageal, Gastric, Kidney, Liver, Lung, Ovarian, Pancreatic, Prostate, Uterine and AML


A011502 : Adjuvant Breast
A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: the ABC trial
EA1181: First-Line Stage II and IIIa HER2+ prior to TX Breast Cancer
§ (Compass HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
S1418 : Adjuvant Breast Triple Negative
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
NRG- BR004 : First-line HER2+ Metastatic Breast
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer


1st-line Locally Advanced/Metastatic Urothelial Cancer – MK7902-011
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

Our Team


Medical Director of Clinical Research

Dr. Nafisa Burhani, MD

Manager of Clinical Research

Karen Sceniak, CCRC

Clinical Research Coordinators


Data Manager


Regulatory Affairs Manager